Top Page
Isofol Medical AB
(ISOFOL)
Isofol Medical AB (ISOFOL) vs. iShares MSCI Sweden ETF (EWD)
Isofol Medical AB Business Overview & Revenue Model
Isofol Medical AB Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 721.00K | 12.80M | 22.41M |
| Gross Profit | 0.00 | -38.73M | -34.41M | -165.71M | -174.31M |
| EBITDA | -54.76M | -47.21M | -37.02M | -159.73M | -198.49M |
| Net Income | -54.17M | -43.49M | -37.07M | -159.79M | -200.25M |
Balance Sheet | |||||
| Total Assets | 129.40M | 98.42M | 140.60M | 213.46M | 401.36M |
| Cash, Cash Equivalents and Short-Term Investments | 126.99M | 96.16M | 138.15M | 190.58M | 379.45M |
| Total Debt | 0.00 | 0.00 | 0.00 | 3.95M | 1.65M |
| Total Liabilities | 21.52M | 20.47M | 19.16M | 54.99M | 83.13M |
| Stockholders Equity | 107.87M | 77.94M | 121.43M | 158.48M | 318.23M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -41.99M | -52.54M | -190.97M | -188.43M |
| Operating Cash Flow | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Investing Cash Flow | 0.00 | 0.00 | 101.00K | 0.00 | 0.00 |
| Financing Cash Flow | 84.07M | 0.00 | 0.00 | 23.00K | 450.48M |
Isofol Medical AB Technical Analysis
Isofol Medical AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr185.53M | -2.92 | -51.35% | ― | ― | -34.02% | |
45 Neutral | kr105.97M | -1.66 | -1291.15% | ― | ― | 28.54% | |
43 Neutral | kr135.90M | -1.72 | -199.86% | ― | 69.03% | 23.10% | |
43 Neutral | kr35.15M | -1.03 | -457.91% | ― | ― | -19.35% | |
41 Neutral | kr202.40M | -4.03 | ― | ― | -7.68% | 17.93% |
Isofol Medical AB Corporate Events
Isofol Medical has expanded its global exclusive license for its lead candidate arfolitixorin to cover development and commercialization in autism spectrum disorder, specifically targeting patients with cerebral folate deficiency, a subgroup believed to benefit from folate-based therapies. The company has also filed a related patent application and initiated an exploratory pre-clinical study, positioning itself to capture emerging opportunities in autism while maintaining its primary strategic focus on advancing arfolitixorin for colorectal cancer, where it sees a significant unmet medical need and potential treatment gap in oncology care.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.64 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
Isofol Medical has set the subscription price for its series TO1 warrants at SEK 0.48 per share, equal to 70 percent of the recent volume-weighted average share price, with an exercise window running from 16 to 30 March 2026. Full exercise of the 39,863,928 warrants could raise about SEK 19.1 million, increasing the share count by roughly 12.4 percent and diluting existing shareholders accordingly.
To bolster the warrant exercise, Isofol has secured a top guarantee commitment from partner Solasia Pharma covering about 5.3 percent of potential proceeds, alongside non-binding letters of intent from major shareholders, management and the board representing a further 36 percent. Together these commitments, provided without compensation, cover around 42 percent of the possible capital raise, signalling internal and partner support but leaving execution risk as warrants will expire worthless if not exercised or sold by the stated deadlines.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.64 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
Isofol Medical has secured a top guarantee commitment from major shareholder Solasia Pharma and non-binding letters of intent from other large shareholders, its board and management to support the upcoming exercise of series TO1 warrants. Together these commitments cover 42 percent of the potential proceeds from the warrants, whose final exercise price will be set at a discount to the recent Nasdaq Stockholm share price ahead of the March 16–30 subscription window.
The guarantee from Solasia, Isofol’s Japanese development and commercialisation partner for arfolitixorin, and the letters of intent are provided free of charge but remain unsecured and non-binding, leaving some execution risk despite the signalling of confidence from key stakeholders. If the guarantee is called, Isofol’s board plans a directed share issue on identical terms to the warrant exercise, a move that could bolster the company’s funding base as it advances oncology trials in Japan and other markets.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.64 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
Isofol’s nomination committee has proposed the re-election of all current board members and the appointment of major shareholder Christian Haglund as a new director at the company’s annual general meeting on May 19, 2026. The proposal would expand the board to six members, reflecting a stronger investor presence through Haglund, a seasoned finance and capital markets executive who holds about 10.5% of Isofol’s shares and sits on several other Swedish corporate boards.
Haglund, co-founder of real estate groups Intea Fastigheter and Vacse and former CFO and deputy CEO at Intea, brings extensive experience in financial investments, including previous roles at Atlas Copco and as an advisor to the Epiroc Group’s Swedish pension fund. The nomination committee, which includes Haglund himself among other large shareholders, plans to publish full proposals ahead of the meeting, signaling a governance approach that closely aligns board composition with the company’s key owners and capital markets expertise.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.64 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
Isofol Medical AB, listed on Nasdaq Stockholm, develops arfolitixorin, a proprietary folate-based drug candidate intended to boost the effectiveness of established cancer therapies, particularly in colorectal cancer. The company is running a phase Ib/II trial with an optimized dosing regimen at the Charité University Hospital in Germany, targeting a significant treatment gap in one of the world’s most common and deadly cancers.
The company will present its progress and outlook to the investment community at two Swedish investor events in March: Life Science Day in Gothenburg on March 4 and Stora Aktiedagarna on March 10. Both presentations, delivered by CEO Petter Segelman Lindqvist, will be broadcast online and made available on demand, underscoring Isofol’s efforts to raise visibility and engage shareholders as it advances its key oncology asset.
The most recent analyst rating on (SE:ISOFOL) stock is a Sell with a SEK0.72 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
Isofol Medical has reported encouraging interim data from its ongoing phase Ib/II study of arfolitixorin in RAS-mutated metastatic colorectal cancer, an especially hard-to-treat patient group. Conducted initially at Charité – Universitätsmedizin Berlin, the trial is testing an optimized dosing regimen and is now assessing a third dose level of 300 mg/m2, with plans to expand to additional hospitals and a broader phase II cohort including a control arm.
All patients evaluated so far have shown tumor shrinkage without dose-limiting side effects, with reductions in total tumor burden of up to about 50 percent. Notably, half of the six patients assessed have responded so strongly that they were taken off study to be considered for tumor surgery, a rare possibility in this population, underscoring the potential of arfolitixorin to address a major treatment gap in colorectal cancer, the world’s third most common malignancy and a leading cause of cancer death.
Investigators and company management describe the results as unexpectedly positive, highlighting both the apparent safety and the early efficacy signal from the new dosing strategy. Isofol plans to present additional data from the trial at medical conferences later in the year, a development that could influence its clinical strategy and strengthen its positioning in the competitive oncology drug-development landscape.
The most recent analyst rating on (SE:ISOFOL) stock is a Sell with a SEK0.56 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
Isofol Medical AB continued development of its lead cancer drug candidate arfolitixorin during the fourth quarter of 2025, advancing a phase Ib/II study in metastatic colorectal cancer with dose escalation up to 300 mg/m² and planning a phase II start later in 2026. The company reported a quarterly loss of kSEK 12,777 and a full-year loss of kSEK 54,168 with no revenue, but ended the year with kSEK 126,990 in cash and proposed no dividend, underlining its development-stage and cash-consuming profile.
Arfolitixorin attracted significant international attention as Isofol presented its study design at major oncology conferences ESMO in Berlin and ASCO-GI in the U.S., while also courting investors and partners at J.P. Morgan Week and Nordic investor events. The European Patent Office’s decision to grant a new product patent for arfolitixorin with protection until 2043 strengthens Isofol’s intellectual property position and supports its strategy to make arfolitixorin a cornerstone of future first-line cancer therapies, including through collaboration with Japanese partner Solasia Pharma K.K.
Management signals 2026 as a pivotal year, with expected data readouts from ongoing studies, further regulatory and partnering activities, and preparation for expansion of arfolitixorin into additional indications beyond metastatic colorectal cancer. This combination of advancing clinical development, reinforced patent protection and active investor and partner engagement could enhance Isofol’s competitive standing in oncology drug development while concentrating execution risk around the coming clinical milestones.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.61 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
Isofol Medical AB will participate in the ASCO GI Cancer Symposium in San Francisco, where it will present a Trial in Progress abstract outlining the design and recruitment status of its ongoing phase Ib/II study of arfolitixorin in metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, tests a new dosing regimen and escalating doses of arfolitixorin in combination with 5-FU chemotherapy, oxaliplatin and bevacizumab as first-line treatment, underscoring the candidate’s potential to address a significant treatment gap in one of the world’s most common and deadly cancers. Company executives describe the congress appearance and planned advisory-board meetings as an important start to the year, as Isofol aims to complete the first part of the trial and move into phase II, a step that could prove pivotal for its clinical development program and its positioning in colorectal cancer therapeutics.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.69 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.